BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
Head and Neck Cancers Oral Cavity
VM Oncology, LLCSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Head and Neck Cancers Oral Cavity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Pembrolizumab VM Oncology, LLC | Phase 1/2 | CCC |
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
Cetuximab National Cancer Institute (NCI) | Phase 1 | CC |
Cord Blood-Derived Expanded Allogeneic Natural Killer Cells M.D. Anderson Cancer Center | Phase 1 | CC |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 1 | CC |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →